Selected publication milestones through 9 October 2026. These dates identify source publication years, not priority claims or a comprehensive history.
1979 — Finnish hospital dietary periods test cholesterol and coronary outcomes in a limited historical design. PMID 393644.
1989 — Original Minnesota trial clinical report; one parent study with the later reanalysis. PMID 2643423.
2013 — Recovered Sydney trial data sharpen uncertainty about intervention composition and mortality. PMID 23386268.
2016 — Recovered Minnesota data distinguish lipid response from observed mortality. PMID 27071971.
2017 — FOURIER tests pharmacological LDL lowering with clinical event endpoints. PMID 28304224.
2020 — Multivariable genetics prioritizes apoB across correlated lipid measures. PMID 32203549.
2024 — RISSCI-1 documents heterogeneous responses in a sequential design. PMID 39111551.
2026 — Response-selected RISSCI-2 examines a proposed absorption explanation. PMID 42664559.
Selective diet-specific clinical mediation remains weaker than particle causality.
Cis-MUFA and cis-PUFA, individual SFA species and food matrices need separate effect estimates.
Historical trans-fat exposure and incomplete data recovery remain unresolved; contamination must not be asserted as an established explanation of nulls.
Mean response and responder-defined follow-up are distinct populations.
More diverse clinical populations and complete correction/supplement checks are needed.
Independently run, preregistered long-term isoenergetic replacement trial with fixed SFA species, cis-PUFA/cis-MUFA comparators, matched food matrices, trans-fat measurement, sustained apoB separation and blinded adjudicated ASCVD outcomes; prospectively test mediation and competing metabolic pathways.